Hirudin Plus Aspirin in the Secondary Prevention of Cardioembolic Stroke Due to Nonvalvular Atrial Fibrillation

CompletedOBSERVATIONAL
Enrollment

239

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

October 31, 2018

Conditions
Cardioembolic StrokeAtrial Fibrillation
Interventions
DRUG

hirudin plus aspirin

natural hirudin 0.75g, three times a day (Brand name: Maixuekang capsule, Guizhou Xinbang Pharmaceutical Co., China) and aspirin 100mg, once daily

DRUG

Warfarin

an initial dose of 1.25mg once daily. Three days later, INR of patients was checked every three days and the dose of warfarin was adjusted until reach the target range of 2 to 3. Since then INR monitoring was performed at 1, 2, 3, 6, 9, 12 months after stroke onset, targeting an INR between 2 and 3 and the dose of warfarin was adjusted accordingly.

Trial Locations (1)

710032

Xijing Hospital, Xi'an

All Listed Sponsors
collaborator

Xi'an Central Hospital

OTHER

collaborator

Shaanxi people's Hospital

UNKNOWN

collaborator

The Third Hospital of PLA

UNKNOWN

collaborator

Hanzhong Central Hospital

OTHER

collaborator

Xianyang 215 hospital

UNKNOWN

collaborator

Yulin Second Hospital

UNKNOWN

collaborator

Yan'an University Affiliated Hospital

OTHER

collaborator

Baoji Central Hospital

OTHER

collaborator

Ankang Central Hospital

OTHER

collaborator

Baoji People's Hospital

UNKNOWN

collaborator

Yan'an people's Hospital

UNKNOWN

collaborator

451 Hospital

UNKNOWN

collaborator

Shangluo Central Hospital

OTHER

collaborator

Central Hospital of China Railway 20th Bureau

UNKNOWN

collaborator

Xiangyang Central Hospital

OTHER

collaborator

Xi'an Ninth Hospital

UNKNOWN

collaborator

Shangluo Second People's Hospital

UNKNOWN

lead

Xijing Hospital

OTHER

NCT02181361 - Hirudin Plus Aspirin in the Secondary Prevention of Cardioembolic Stroke Due to Nonvalvular Atrial Fibrillation | Biotech Hunter | Biotech Hunter